Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
HCG clinicians contributing to one of the largest bodies of oncology research from India
Subscribe To Our Newsletter & Stay Updated
